O'Hara Gilles E, Philippon François, Champagne Jean, Blier Louis, Molin Franck, Côté Jean-Marc, Nault Isabelle, Sarrazin Jean-François, Gilbert Marcel
Institut Universitaire de Cardiologie et de Pneumologie, Hopital Laval, Sainte-Foy, Quebec.
Can J Cardiol. 2007 Oct;23 Suppl B(Suppl B):67B-70B. doi: 10.1016/s0828-282x(07)71013-9.
Catheter ablation is a curative treatment with excellent success and minimal complication rates for patients with supraventricular or ventricular arrhythmias.
The acute outcomes and complications of all catheter ablation procedures for supraventricular and ventricular arrhythmias performed at the Quebec Heart Institute (Sainte-Foy, Quebec) during a 14-year period from January 1, 1993, to December 31, 2006, were prospectively assessed. The ablation procedures were classified according to the arrhythmias induced using standard electrophysiological techniques and definitions. Immediate success and complication rates were prospectively included in the database.
A total of 5330 patients had catheter ablation performed at the Institute during the period assessed. The mean (+/- SD) age of patients was 50 +/- 18 years (range four to 97 years), and 2340 patients (44%) were men. Most of the patients were younger than 75 years (group 1), and 487 (9%) were 75 years of age and older (group 2). Indications for ablations were as follows: atrioventricular nodal re-entry tachycardia (AVNRT) in 2263 patients, accessory pathways in 1147 patients, atrioventricular node ablation in 803 patients, typical atrial flutter in 377 patients and atrial tachycardia in 160 patients; 580 patients had other ablation procedures. The overall success rates were 81% for atrial tachycardia, 92% for accessory pathways or flutter, and 99% for AVNRT or atrioventricular node ablation. There was no difference in the success rates of the younger (group 1) and older (group 2) patients. Seventy-seven patients (1.4%) had complications, including 11 major events (myocardial infarction in one patient, pulmonary embolism in three patients and permanent pacemaker in seven patients). In patients undergoing AVNRT ablation, two had a permanent pacemaker implanted immediately after the procedure and three had a permanent pacemaker implanted at follow-up.
The results confirm that radiofrequency ablation is safe and effective, supporting ablation therapy as a first-line therapy for the majority of patients with cardiac arrhythmias.
导管消融术是一种根治性治疗方法,对于室上性或室性心律失常患者,成功率高且并发症发生率低。
前瞻性评估了1993年1月1日至2006年12月31日这14年间在魁北克心脏研究所(魁北克省圣福瓦)进行的所有室上性和室性心律失常导管消融手术的急性结果和并发症。根据使用标准电生理技术和定义诱发的心律失常对消融手术进行分类。即时成功率和并发症发生率被前瞻性纳入数据库。
在评估期间,该研究所共有5330例患者接受了导管消融术。患者的平均(±标准差)年龄为50±18岁(范围为4至97岁),2340例患者(44%)为男性。大多数患者年龄小于75岁(第1组),487例(9%)患者年龄在75岁及以上(第2组)。消融的适应证如下:房室结折返性心动过速(AVNRT)2263例,旁路1147例,房室结消融803例,典型心房扑动377例,房性心动过速160例;580例患者进行了其他消融手术。房性心动过速的总体成功率为81%,旁路或心房扑动为92%,AVNRT或房室结消融术为99%。年轻患者(第1组)和老年患者(第2组)的成功率没有差异。77例患者(1.4%)出现并发症,包括11例重大事件(1例心肌梗死,3例肺栓塞,7例植入永久性起搏器)。在接受AVNRT消融术的患者中,2例在手术后立即植入了永久性起搏器,3例在随访时植入了永久性起搏器。
结果证实射频消融术安全有效,支持将消融治疗作为大多数心律失常患者的一线治疗方法。